Brightgene Bio-medical Technology Co Ltd
688166
Company Profile
Business description
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Contact
Xinghu Street, Industrial Park
Building C25-C28, Bio-Nano Park, No. 218
Suzhou215123
CHNT: +86 51262620988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,196
Stocks News & Analysis
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,700.90 | 32.40 | 0.37% |
| CAC 40 | 7,769.31 | 77.24 | -0.98% |
| DAX 40 | 22,612.97 | 344.11 | -1.50% |
| Dow JONES (US) | 45,960.11 | 469.38 | -1.01% |
| FTSE 100 | 9,972.17 | 134.67 | -1.33% |
| HKSE | 24,856.43 | 479.52 | -1.89% |
| NASDAQ | 21,408.08 | 521.74 | -2.38% |
| Nikkei 225 | 53,603.65 | 145.97 | -0.27% |
| NZX 50 Index | 12,942.21 | 34.78 | -0.27% |
| S&P 500 | 6,477.16 | 114.74 | -1.74% |
| S&P/ASX 200 | 8,507.30 | 35.70 | 0.42% |
| SSE Composite Index | 3,889.08 | 42.75 | -1.09% |